UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):August 5, 2004
Anadys Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)
| Delaware | 23-3193172 | |||
| (State or Other Jurisdiction | (Commission File | (I.R.S. Employer | ||
| of Incorporation) | Number) | Identification No.) |
| 3115 Merryfield Row | 92121 | |
| San Diego, California | (Zip Code) | |
| (Address of Principal | ||
| Executive Offices) |
Registrant’s telephone number, including area code:(858) 530-3600
Item 7. Financial Statements and Exhibits.
(c) Exhibits.
| Exhibit No. | Description | |
| 99.1 | Press Release dated August 5, 2004 |
Item 12. Results of Operations and Financial Condition
On August 5, 2004, Anadys Pharmaceuticls, Inc. issued a press release announcing its financial results for the three and six months ended June 30, 2004. A copy of this press release is attached hereto as Exhibit 99.1, which is furnished under Item 12 of this report and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.
SIGNATURES
Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: August 5, 2004 | Anadys Pharmaceuticals, Inc. | |||||
| By: | /s/ Michael Kamdar | |||||
| Michael Kamdar Senior Vice President, Corporate Development and Finance | ||||||
